Columbia Labs
This article was originally published in The Tan Sheet
Executive Summary
Signs letter-of-intent agreement giving Lake Pharmaceutical exclusive U.S. rights to market Advantage 24, a nonoxynol-9 sustained-release contraceptive gel using Columbia's bioadhesive technology. Advantage 24 is set to be launched by September and expected to be in "close to 40,000 outlets by the end of 1995," Columbia said. Safety trials by the World Health Organization have been completed on the use of Advantage 24 in preventing transmission of STDs; WHO is expected to begin efficacy trials soon ("The Tan Sheet" April 11, p. 11)